Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of finerenone in pediatric heart failure with left ventricular systolic dysfunction
MOH_2026-01-04_015581Phase 3Not yet recruiting
- Sponsor
- Bayer
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of finerenone in heart failure (HF) and left ventricular systolic dysfunction (LVSD), sponsored by Bayer. Primary endpoint: Treatment-emergent adverse events. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on MOH_2026-01-04_015581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-04_015581.